🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

34 results for “Yan” Clear

  1. 5 mg prednisone

    Ultragenyx UK Limited

    Granulomatosis With Polyangiitis

    phase 3 small molecule active

    2 trials

  2. Houyanqing Oral Liquid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Cancinoma (NPC)

    phase 3 small molecule active

    1 trial

  3. Ilaprazole

    Yang Xiaotian

    Erosive Esophagitis

    phase 3 small molecule completed

    1 trial

  4. Nucala 100 mg powder for solution for injection, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, SODIUM CHLORIDE, PLACEBO D AZATHIOPRINE

    Pari Pharma GmbH

    Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome

    phase 3 small molecule active

    1 trial

  5. Placebo for Mepolizumab Injection, MEPOLIZUMAB, Placebo for Depemokimab Injection

    GlaxoSmithKline

    Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

    phase 3 small molecule active

    1 trial

  6. Placebo for mepolizumab is a 0.9% sodium chloride solution in a syringe for subcutaneous injection., PREDNISOLONE, MEPOLIZUMAB, METHYLPREDNISOLONE, PREDNISONE, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Eosinophilic Granulomatosis with Polyangiitis (EGPA)

    phase 3 small molecule active

    1 trial

  7. Blood test

    Yang Xiaotian

    Cancer of Colon

    phase 2 other completed

    1 trial

  8. Bu-Yang-Huan-Wu Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ischemic Stroke

    phase 2 small molecule active

    1 trial

  9. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    The George Institute

    relapsed/refractory Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  10. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    PR3-ANCA granulomatosis with polyangiitis (Wegener’s)

    phase 2 small molecule active

    1 trial

  11. INDOCYANINE GREEN

    Fondazione Telethon ETS

    Patients with gynecological cancers undergoing pelvic exenteration

    phase 2 small molecule active

    1 trial

  12. INDOCYANINE GREEN

    The George Institute

    Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery

    phase 2 small molecule active

    1 trial

  13. NS-229 matching tablets with no active treatment, NS-229

    Lacuna Pharma Pty Ltd

    Eosinophilic granulomatosis with polyangiitis (EGPA)

    phase 2 small molecule active

    1 trial

  14. Yi Qi Yang Yin Decoction

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Sjögren Syndrome

    phase 2 small molecule active

    1 trial

  15. Single Dose Pharmacokinetics and Relative Bioavailability of Sayana Press via Upper Arm Injection Relative to Anterior Thigh and Abdomen

    Pfizer Australia Pty Ltd

    long-term female contraception

    phase 1 other active

    1 trial

  16. Yang Yin Fu Zheng Jie Du therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  17. Yiqi Wenyang Sanhan Formula Combined with Acupoint Application

    Universal Integrated

    Allergic Rhinitis With Asthma

    phase 1 small molecule active

    1 trial

  18. INDOCYANINE GREEN

    Disc Medicine

    cervical cancer stage I-IIA

    approved small molecule active

    1 trial

  19. INDOCYANINE GREEN

    The George Institute

    Patients with liver tumors that will undergo minimally invasive liver surgery

    approved small molecule active

    1 trial

  20. Ilaprazole

    Yang Xiaotian

    Gastric Cancer

    approved small molecule completed

    1 trial

  21. MEPOLIZUMAB

    Disc Medicine

    Eosinophilic Granulomatosis with Polyangiitis (eGPA)

    approved small molecule active

    1 trial

  22. Nifedipine 30 MG

    Yang I. Pachankis

    Severe Acute Respiratory Syndrome-related Coronavirus

    approved small molecule completed

    1 trial

  23. Reyanning mixture

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Tonsillitis

    approved small molecule active

    1 trial

  24. 95% condensed proanthocyanidins from grape seed extract

    United Therapeutics Europe Ltd

    Iron Deficiency Anemia

    other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources